Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

van de Berg S.E.J., Pelzer P.T., van der Land A.J., Abdrakhmanova E., Ozi A.M., Arias M., Cook-Scalise S., Dravniece G., Gebhard A., Juneja S., Handayani R., Kappel D., Kimerling M., Koppelaar I., Malhotra S., Myrzaliev B., Nsa B., Sugiharto J., Engel N., Mulder C., van den Hof S.

KNCV Tuberculosis foundation, The Hague, Netherlands; National TB Program Kyrgyzstan, Bishkek, Kyrgyzstan; National Tuberculosis and Leprosy control Program Nigeria, Mabushi, Nigeria; TB AllianceNY, United States; PATH, Kyiv, Ukraine; National TB Program Indonesia, Jakarta, Indonesia; KNCV country office Kyrgyzstan, Bishkek, Kyrgyzstan; KNCV country office Nigeria, Abuja, Nigeria; Yayasan KNCV Indonesia, Jakarta, Indonesia; Maastricht University, Maastricht, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam University Medical Center, Amsterdam, Netherlands; National Institute for Public Health and the Environment, Bilthoven, Netherlands


Abstract

Background: BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, and success rates, and hence to limit patient burden, loss to follow-up and the emergence of resistance it is essential to implement new DR-TB regimens. The objective of this study was to assess the acceptability, feasibility, and likelihood of implementing BPaL in Indonesia, Kyrgyzstan, and Nigeria. Methods: We conducted a concurrent mixed-methods study among a cross-section of health care workers, programmatic and laboratory stakeholders between May 2018 and May 2019. We conducted semi-structured interviews and focus group discussions to assess perceptions on acceptability and feasibility of implementing BPaL. We determined the proportions of a recoded 3-point Likert scale (acceptable; neutral; unacceptable), as well as the overall likelihood of implementing BPaL (likely; neutral; unlikely) that participants graded per regimen, pre-defined aspect and country. We analysed the qualitative results using a deductive framework analysis. Results: In total 188 stakeholders participated in this study: 63 from Kyrgyzstan, 51 from Indonesia, and 74 from Nigeria The majority were health care workers (110). Overall, 88% (146/166) of the stakeholders would likely implement BPaL once available. Overall acceptability for BPaL was high, especially patient friendliness was often rated as acceptable (93%, 124/133). In contrast, patient friendliness of the ITR was rated as acceptable by 45%. Stakeholders appreciated that BPaL would reduce workload and financial burden on the health care system. However, several stakeholders expressed concerns regarding BPaL safety (monitoring), long-term efficacy, and national regulatory requirements regarding introduction of the regimen. Stakeholders stressed the importance of addressing current health systems constraints as well, especially in treatment and safety monitoring systems. Conclusions: Acceptability and feasibility of the BPaL regimen is high among TB stakeholders in Indonesia, Kyrgyzstan, and Nigeria. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints. © 2021, The Author(s).

Acceptability; BPaL; Feasibility; Implementation; Novel TB regimen; Pretomanid; XDR-TB


Journal

BMC Public Health

Publisher: BioMed Central Ltd

Volume 21, Issue 1, Art No 1404, Page – , Page Count


Journal Link: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110488627&doi=10.1186%2fs12889-021-11427-y&partnerID=40&md5=ada868b6e70a35842416a853a1c643e1

doi: 10.1186/s12889-021-11427-y

Issn: 14712458

Type: All Open Access, Gold, Green


References

(2019) Global Tuberculosis Report 2019; Kurz, S.G., Furin, J.J., Bark, C.M., Drug-resistant tuberculosis: challenges and Progress (2016) Infect Dis Clin N Am, 30 (2), pp. 509-522; (2014) Companion Handbook: World Health Organization, , https://apps.who.int/iris/bitstream/handle/10665/130918/?sequence=1; (2014) The End TB Strategy; Conradie, F., Diacon, A.H., Ngubane, N., Howell, P., Everitt, D., Crook, A.M., Mendel, C.M., Spigelman, M., Treatment of highly drug-resistant pulmonary tuberculosis (2020) N Engl J Med, 382 (10), pp. 893-902; (2020) WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment; (2020) Pretomanid FGK. European Medicines Agency, , https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pretomanid-fgk_en.pdf, Available at:, Accessed 6 July 2021; (2019) Drug Trials Snapshots: Pretomanid., , https://www.fda.gov/drugs/drug-approvals-anddatabases/drug-trials-snapshots-pretomanid, Available at, Accessed 6 July 2021; Wells, W.A., Ge, C.F., Patel, N., Oh, T., Gardiner, E., Kimerling, M.E., Size and usage patterns of private TB drug markets in the high burden countries (2011) PLoS One, 6 (5); Thomas, B.E., Shanmugam, P., Malaisamy, M., Ovung, S., Suresh, C., Subbaraman, R., Adinarayanan, S., Nagarajan, K., Psycho-socio-economic issues challenging multidrug resistant tuberculosis patients: a systematic review (2016) PLoS One, 11 (1); Atun, R., De Jongh, T., Secci, F., Ohiri, K., Adeyi, O., Integration of targeted health interventions into health systems: a conceptual framework for analysis (2010) Health Policy Plan, 25 (2), pp. 104-111; Squires, J.E., Graham, I.D., Hutchinson, A.M., Michie, S., Francis, J.J., Sales, A., Brehaut, J., Grimshaw, J.M., Identifying the domains of context important to implementation science: a study protocol (2015) Implement Sci, 10 (1), p. 135; May, C.R., Johnson, M., Finch, T., Implementation, context and complexity (2016) Implement Sci, 11 (1), p. 141; (2018) Global Tuberculosis Report, 2018; Surya, A., Setyaningsih, B., Suryani Nasution, H., Gita Parwati, C., Yuzwar, Y.E., Osberg, M., Hanson, C.L., Waworuntu, W., Quality tuberculosis Care in Indonesia: using patient pathway analysis to optimize public-private collaboration (2017) J Infect Dis, 216, pp. S724-S732; (2017) Implementation Research for Universal Health Coverage in Indonesia, pp. 1-14; (2014) Review of tuberculosis prevention and care services in Kyrgyzstan Mission report; Challenge, T.B., (2017) Kyrgyzstan year 3 annual technical performance report Oct 2016 – Sep 2017; Mukherjee, D.S., (2015) Green light committee monitoring Mission Nigeria; Creswell, J.W., Plano Clark, V.L., (2017) Designing and conducting mixed methods research; Vega, P., Psychiatric issues in the management of patients with multidrug-resistant tuberculosis (2004) Int J Tuberc Lung Dis, 8 (6), pp. 749-759. , COI: 1:STN:280:DC%2BD2c3ot1Whsg%3D%3D, PID: 15182146; Charyeva, Z., Curtis, S., Mullen, S., Senik, T., Zaliznyak, O., What works best for ensuring treatment adherence. Lessons from a social support program for people treated for tuberculosis in Ukraine (2019) PLoS One, 14, pp. 1-13; Deshmukh, R.D., Dhande, D.J., Sachdeva, K.S., Patient and provider reported reasons for lost to follow up in MDRTB treatment: A qualitative study from a drug resistant TB centre in India (2015) Plos One, pp. 1-11. , https://doi.org/10.1371/journal.pone.0135802; Tupasi, T., Garfin, A.M.C.G., Mangan, J.M., Orillaza-Chi, R., Naval, L.C., Balane, G.I., Basilio, R., Kurbatova, E.V., Multidrug-resistant tuberculosis patients’ views of interventions to reduce treatment loss to follow-up (2017) Int J Tuberc Lung Dis, 21 (1), pp. 23-31; Mulder, C., Rupert, S., Setiawan, E., (2020) BPaL for treating extensively drug resistant tuberculosis: a cost analysis submitted for publication; Horter, S., Stringer, B., Reynolds, L., Shoaib, M., Kasozi, S., Casas, E.C., Verputten, M., du Cros, P., ‘Home is where the patient is’: a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis (2014) BMC Health Serv Res, 14 (1), p. 81; (2017) Safety and efficacy of various doses and treatment durations of Linezolid Plus Bedaquiline and Pretomanid in participants with Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix), pp. 1-17. , https://clinicaltrials.gov/show/NCT03086486; Nguyen, T.V.A., Anthony, R.M., Bañuls, A.L., Nguyen, T.V.A., Vu, D.H., Alffenaar, J.W.C., Bedaquiline resistance: its emergence, mechanism, and prevention (2018) Clin Infect Dis, 66 (10), pp. 1625-1630; (2015) Department of Public Health, Federal Ministry of Health. the National Strategic Plan for Tuberculosiscontrol 2015-2020, , http://ntblcp.org.ng/strategic-plan, Available at, Accessed 6 July 2021; Gurbanova, E., (2017) Regional green light Commitee for Europe Mission for technical assistance on implementation of the National M/XDR-TB response plan in Kyrgyzstan; (2015) National Strategy for Tuberculosis Control 2015–2019 – Draft

Indexed by Scopus

Leave a Comment